New device aims to fix lingering aortic tears after emergency surgery

NCT ID NCT07402252

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device designed to repair remaining tears in the aorta after initial emergency surgery for a serious condition called type A aortic dissection. About 198 adults who still have a tear in their aorta after their first surgery will be randomly assigned to either get the new device plus standard care, or just standard care (medication to control blood pressure). The goal is to see if the device helps the aorta heal better and reduces complications over the next year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Type A Dissection Total Endovascular Reconstruction System (a device used to repair remaining tears in the aorta)

What this could lead to

If successful, this device could offer a safer, more effective way to treat residual aortic dissections, potentially reducing the need for lifelong medication and preventing future complications.

What could go wrong

This is an early-stage trial with only 198 participants, so results may not apply to everyone. The device is new and carries risks like any surgical procedure, including bleeding or infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL DISSECTION AFTER REPAIR FOR TYPE A AORTIC DISSECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••